Patents Examined by Deepak R. Rao
  • Patent number: 10813933
    Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: October 27, 2020
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Ryohei Katayama, Ken Uchibori, Naoya Fujita
  • Patent number: 10793576
    Abstract: The present invention provides a compound having a structure shown in formula (I) or an isomer, pharmaceutically acceptable solvate, or salt thereof. The compound is used as a Bruton's tyrosine kinase inhibitor, and has a higher inhibitory activity against BTK and less adverse effects.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: October 6, 2020
    Assignees: CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD., CHENGDU HIGHBRED PHARMACEUTICAL CO., LTD.
    Inventors: Yingfu Li, Haoxi Huang, Guanfeng Liu, Tonghui Chen, Junfeng Ren, Zhonghai Su
  • Patent number: 10787438
    Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: September 29, 2020
    Assignee: Pfizer Inc.
    Inventors: Matthew Dowling, Dilinie Fernando, Kentaro Futatsugi, Kim Huard, Thomas Victor Magee, Brian Raymer, Andre Shavnya, Aaron Smith, Benjamin Thuma, Andy Tsai, Meihua Tu
  • Patent number: 10780090
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: September 22, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Matthew O. Duffey, Dylan England, Brian Scott Freeze, Zhigen Hu, Steven Langston, Charles McIntyre, Hirotake Mizutani, Koji Ono, He Xu
  • Patent number: 10781192
    Abstract: Disclosed herein are methods for preparing [(2S,3R)—N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: September 22, 2020
    Assignee: KEZAR LIFE SCIENCES
    Inventors: Henry Johnson, Sean Dalziel, Dustin McMinn
  • Patent number: 10781210
    Abstract: The present invention provides a compound having TrkA inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention relates to a compound represented by Formula (I): wherein ?X is ?O or the like, R5 and R5A are hydrogen atoms or the like, —A— is —NR1— or the like, B is substituted or unsubstituted aromatic carbocyclyl or the like, R1 is substituted or unsubstituted alkyl or the like, R2 is a hydrogen atom or the like, —W— is —CH2— or the like, —WA— is —CH2— or the like, R13 is substituted or unsubstituted aromatic carbocyclyl or the like, R14 is substituted or unsubstituted aromatic heterocyclyl or the like, R15 is substituted or unsubstituted alkyl or the like, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: September 22, 2020
    Assignee: Shionogi & Co., Ltd.
    Inventors: Akira Yukimasa, Kazuya Kano, Kenichiroh Nakamura, Takatsugu Inoue, Motohiro Fujiu
  • Patent number: 10781200
    Abstract: Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: September 22, 2020
    Assignee: ATTUNE PHARMACEUTICALS, INC.
    Inventors: Andrew McDonald, Shawn Qian
  • Patent number: 10774082
    Abstract: [Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: September 15, 2020
    Assignee: Astellas Pharma Inc.
    Inventors: Kazuyuki Kuramoto, Michinori Akaiwa, Tomoaki Abe, Takanobu Araki, Susumu Yamaki, Shigeki Kunikawa, Tomoyoshi Imaizumi, Takahiro Nigawara, Keisuke Arakawa, Itsuro Shimada, Masashi Shimazaki, Yoshiki Satake, Kazushi Watanabe, Takanori Koike
  • Patent number: 10774090
    Abstract: The present invention discloses a compound comprising the formula: wherein R is hydrogen or an alkyl group having from one to ten carbon atoms, or a compound of the formula wherein the S is replaced by CH2 or O, and optionally comprising a pharmaceutically acceptable salt or hydrate thereof. A method of treating a patient having cancer or a disease comprising administering to a patient an effective amount of the compound or pharmaceutically acceptable salt or hydrate thereof.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: September 15, 2020
    Assignee: Duquesne University of the Holy Spirit
    Inventor: Aleem Gangjee
  • Patent number: 10770661
    Abstract: The present invention discloses a thermally activated delayed fluorescence material and application thereof in an organic electroluminescence device. The thermally activated delayed fluorescence material is a compound having the general structure of Formula I or Formula II: In Formula I and Formula II, R1 is a cyano, p is 1, 2 or 3, q is 1, 2 or 3, m is 1 or 2, n is 1 or 2, Ar1 is a phenyl substituted with one or more groups selected from C1-6 alkyl, methoxy, ethoxy, or phenyl, Ar2 and Ar3 are selected from the following groups: and X is bromine or iodine. The present invention further discloses application of the thermally activated delayed fluorescence material as a host material or a luminescent dye of a luminescent layer of an organic electroluminescence device.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: September 8, 2020
    Assignees: KUNSHAN GP-VISIONOX OPTO-ELECTRONICS CO., LTD., TSINGHUA UNIVERSITY
    Inventors: Lian Duan, Dongdong Zhang, Song Liu, Fei Zhao
  • Patent number: 10766901
    Abstract: Provided are a preparation method for a chiral pyrrolopyrimidine compound and a related intermediate. In the method, a compound of formula A and a compound of formula 6 or a salt thereof are reacted to obtain a compound of formula 7 or a compound of formula 14, and a compound of formula I is prepared from the compound of formula 7 or the compound of formula 14. Also provided are the intermediate used, a preparation method for the intermediate and a use of the intermediate in the preparation of the compound of formula I. The preparation method has characteristics such as brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and a convenient post-treatment. The method avoids using an expensive asymmetric reaction catalyst, and is suitable for industrial production.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: September 8, 2020
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD., CENTAURUS BIOPHARMA CO., LTD.
    Inventors: Xiquan Zhang, Aiming Zhang, Zhou Zhou, Huadong Yao, Jie Xie
  • Patent number: 10759814
    Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: September 1, 2020
    Assignee: SHIONOGI & CO., LTD.
    Inventor: Makoto Kawai
  • Patent number: 10758531
    Abstract: Methods for treating HIV or AIDS in a human are provided using two drug regimens comprising a bictegravir and rilpivirine, as well as compositions containing such compounds.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: September 1, 2020
    Assignee: ViiV Healthcare Company
    Inventor: William R. Spreen
  • Patent number: 10752595
    Abstract: The present disclosure relates to novel crystalline forms of a bromodomain protein inhibitor 2-[4-(2-hydroxyethoxy)-3,5-dimethylphenyl]-5,7-dimethoxyquinazolin-4(3H)-one and processes for preparation and use thereof, relating to pharmaceutical industry. Form CS2, Form CS8, Form CS13, Form CS20, Form CS1, Form CS7, Form CS9, Form CS11 and Form CS4 of the present disclosure can be used for preparing drugs treating cardiovascular, cholesterol or lipid-related disorders.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: August 25, 2020
    Assignee: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaoting Zhai, Kaiqiang Yan, Xiaoyu Zhang
  • Patent number: 10738037
    Abstract: The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: August 11, 2020
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Ilaria Candiani, Giovanni Ottaiano, Attilio Tomasi
  • Patent number: 10738032
    Abstract: There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: August 11, 2020
    Assignee: Respivert Limited
    Inventors: Kazuhiro Ito, Catherine Elisabeth Charron, John King-Underwood, Stuart Thomas Onions, Alistair Ian Longshaw, Rudy Broeckx, Walter Filliers, Alex Copmans
  • Patent number: 10736902
    Abstract: A method of treating a patient suffering from TNBC by a multidisciplinary method involving treating the patient with a plurality of the following treatments: i) one or more checkpoint inhibitors; ii) hyperthermia treatment; iii) low dose chemotherapy; iv) Interleukin-2 (IL-2); and v) a compound selected from the group consisting of taurolidine, taurultam, oxathiazin-like compounds, and combinations thereof.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: August 11, 2020
    Assignee: GEISTLICH PHARMA AG
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 10722514
    Abstract: Disclosed herein, inter alia, compounds and methods of use thereof for the modulation of USP7 activity.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 28, 2020
    Assignee: RAPT THERAPEUTICS, INC.
    Inventors: Berenger Biannic, Xinping Han, Dennis X. Hu, John Michael Ketcham, Paul Robert Leger, Jack Maung, Akinori Okano, Jacob Bradley Schwarz, Grant Shibuya, David Juergen Wustrow, Kyle Young
  • Patent number: 10721929
    Abstract: A compound represented by Formula (I) is provided. In Formula (I), Q represents a group represented by Formula Q1, Q2, or Q3, and T represents a chain hydrocarbon group, an alkoxyalkyl group, an alkylsulfanylalkyl group, an alkylsulfinylalkyl group, or an alkylsulfonylalkyl group, which has a halogen atom; a cycloalkylalkyl group or a cycloalkyl group, which has a substituent; OR1, S(O)mR1, OS(O)2R1, CH2OR1, NR1R29, C(O)R1, C(O)NR1R29, NR29C(O)R1, N?CR1R30, or a group represented by any one of Formulas T-1 to T-12.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: July 28, 2020
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Kohei Orimoto, Masaru Shimomura
  • Patent number: 10717713
    Abstract: Novel compositions of matter based on homopiperazine precursor materials and forming a homopiperazine-based ligand are disclosed, along with suitable techniques and materials for the synthesis and utilization thereof. In particular various synthetic schemes and techniques for applying the disclosed compositions of matter as a decontaminating agent. The decontaminating agents include homopiperazine-based ligand-metal complexes that are particularly effective at neutralizing toxicity of nerve agents, pesticides, and other toxic organophosphorus-based compounds. In preferred approaches, the homopiperazine-based ligand-metal complexes act as catalysts to facilitate substitution of a leaving group of the organophosphorus-based compound with a functional group that does not permit the organophosphorus-based compound to inactivate acetylcholinesterase upon introduction of the organophosphorus-based compound to a living organism such as insects and mammals.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: July 21, 2020
    Assignee: Lawrence Livermore National Security, LLC
    Inventors: Carlos A. Valdez, Edmond Y. Lau, Brian P. Mayer